Comparison of the efficacy of a subunit and a live streptomycin‐dependent porcine pleuropneumonia vaccine

Tumamao, J.Q.; Bowles, Ross; Bosch, Han van den; Klaasen, H. L. B. M.; Fenwick, B. W.; Storie, G J; Blackall, P. J.

doi:10.1111/j.1751-0813.2004.tb11108.x

Cited by 44 publications

(44 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limited cross‐serovar protection hampers the efficacy of bacterins that are based on specific serovars (Fenwick & Henry, ). Some subunit vaccines, which contain Apx toxins and either outer membrane proteins or whole bacterial cells, have been commercialized and are reported to convey better cross‐protection than bacterins (Shao et al., ; Thevenon et al., ; Tumamao et al., ; van den Bosch & Frey, ). The commercially available second‐generation subunit vaccines contain four to five recombinant proteins and confer cross‐protection against all serovars to some degree (Meeusen, Walker, Peters, Pastoret, & Jungersen, ).…”

Section: Prevention Control and Treatmentmentioning

confidence: 99%

Update onActinobacillus pleuropneumoniae-knowledge, gaps and challenges

Sassu

Bossé

Tobias

et al. 2017

Transbound Emerg Dis

144

178

View full text Add to dashboard Cite

Summary Porcine pleuropneumonia, caused by the bacterial porcine respiratory tract pathogen Actinobacillus pleuropneumoniae, leads to high economic losses in affected swine herds in most countries of the world. Pigs affected by peracute and acute disease suffer from severe respiratory distress with high lethality. The agent was first described in 1957 and, since then, knowledge about the pathogen itself, and its interactions with the host, has increased continuously. This is, in part, due to the fact that experimental infections can be studied in the natural host. However, the fact that most commercial pigs are colonized by this pathogen has hampered the applicability of knowledge gained under experimental conditions. In addition, several factors are involved in development of disease, and these have often been studied individually. In a DISCONTOOLS initiative, members from science, industry and clinics exchanged their expertise and empirical observations and identified the major gaps in knowledge. This review sums up published results and expert opinions, within the fields of pathogenesis, epidemiology, transmission, immune response to infection, as well as the main means of prevention, detection and control. The gaps that still remain to be filled are highlighted, and present as well as future challenges in the control of this disease are addressed.

show abstract

Section: Prevention Control and Treatmentmentioning

confidence: 99%

Update onActinobacillus pleuropneumoniae-knowledge, gaps and challenges

Sassu

Bossé

Tobias

et al. 2017

Transbound Emerg Dis

144

178

View full text Add to dashboard Cite

show abstract

“…Currently, clinical APP outbreaks are mainly controlled by giving antibiotics to all pigs in an infected facility, whether or not they are clinically affected (Hoflack, Maes, Mateusen, Verdonck, & de Kruif, ; Gottschalk, ). Control and prevention of APP are currently achieved by vaccination (Tumamao et al, ) or the use of antimicrobials such as enrofloxacin, amoxicillin and ceftiofur (Mengelers, Kuiper, Pijpers, Verheijden, & van Miert, ; Hoflack et al, ; Klinkenbeg et al, ). APP serotypes show large differences in virulence and weak cross‐protection capacity among serotypes (Chen, Xiao, & Wen, ).…”

Section: Introductionmentioning

confidence: 99%

Determination of antibacterial agent tilmicosin in pig plasma by LC/MS/MS and its application to pharmacokinetics

Shi-Yue²,

Zhou

et al. 2016

Biomedical Chromatography

View full text Add to dashboard Cite

A rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated to quantify tilmicosin in pig plasma. Plasma samples were prepared by liquid-liquid extraction. Chromatographic separation was achieved on a C column (2.1 × 30 mm, 3.5 μm) using acetonitrile-water (90:10, v/v; water included 0.1% formic acid) as the mobile phase. Mass detection was carried out using positive electrospray ionization in multiple reaction monitoring mode. The calibration curve was linear from 0.5 to 2000 ng/mL (r = 0.9998). The intra- and inter-day accuracy and precision were within the acceptable limits of ±10% for all tilmicosin concentrations. The recoveries ranged from 95 to 99% for the three tested concentrations. The LC-MS/MS method described herein was simple, fast and less laborious than other methods, achieved high sensitivity using a small sample volume, and was successfully applied to pharmacokinetic studies of tilmicosin enteric granules after oral delivery to pigs. In comparison with tilmicosin premix, tilmicosin enteric granules slowed the elimination rate of tilmicosin, prolonged its period of action and significantly improved its bioavailability.

show abstract

“…These subunit vaccines are effective at preventing acute disease, but do not sufficiently protect against colonization and are not widely cross-protective [33,47]. Therefore, further A. pleuropneumoniae outer membrane and/or secreted proteins are screened and tested as candidates for inclusion into next generation vaccines [54].…”

Section: Introductionmentioning

confidence: 99%

Type IV fimbrial subunit protein ApfA contributes to protection against porcine pleuropneumonia

Sadílková

Nepeřený

Vrzal

et al. 2012

Vet Res

View full text Add to dashboard Cite

Porcine pleuropneumonia caused by Actinobacillus pleuropneumoniae accounts for serious economic losses in the pig farming industry worldwide. We examined here the immunogenicity and protective efficacy of the recombinant type IV fimbrial subunit protein ApfA as a single antigen vaccine against pleuropneumonia, or as a component of a multi-antigen preparation comprising five other recombinant antigens derived from key virulence factors of A. pleuropneumoniae (ApxIA, ApxIIA, ApxIIIA, ApxIVA and TbpB). Immunization of pigs with recombinant ApfA alone induced high levels of specific serum antibodies and provided partial protection against challenge with the heterologous A. pleuropneumoniae serotype 9 strain. This protection was higher than that engendered by vaccination with rApxIVA or rTbpB alone and similar to that observed after immunization with the tri-antigen combination of rApxIA, rApxIIA and rApxIIIA. In addition, rApfA improved the vaccination potential of the penta-antigen mixture of rApxIA, rApxIIA, rApxIIIA, rApxIVA and rTbpB proteins, where the hexa-antigen vaccine containing rApfA conferred a high level of protection on pigs against the disease. Moreover, when rApfA was used for vaccination alone or in combination with other antigens, such immunization reduced the number of pigs colonized with the challenge strain. These results indicate that ApfA could be a valuable component of an efficient subunit vaccine for the prevention of porcine pleuropneumonia.

show abstract

Comparison of the efficacy of a subunit and a live streptomycin‐dependent porcine pleuropneumonia vaccine

Cited by 44 publications

References 25 publications

Update onActinobacillus pleuropneumoniae-knowledge, gaps and challenges

Update onActinobacillus pleuropneumoniae-knowledge, gaps and challenges

Determination of antibacterial agent tilmicosin in pig plasma by LC/MS/MS and its application to pharmacokinetics

Type IV fimbrial subunit protein ApfA contributes to protection against porcine pleuropneumonia

Contact Info

Product

Resources

About